sr141716 has been researched along with pyrazolanthrone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Breault, DT; Carlone, DL; de Sousa Casal, J; Dubois, S; Hafner, S; Karp, JM; Mannam, P; Ordovas-Montanes, J; Qi, W; Shah, MS; Stas, E; Syverson, EP; Yin, X; Zeve, D | 1 |
2 other study(ies) available for sr141716 and pyrazolanthrone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Robust differentiation of human enteroendocrine cells from intestinal stem cells.
Topics: Anthracenes; Cell Differentiation; Chromogranin A; Endocannabinoids; Enteroendocrine Cells; Glucagon-Like Peptide 1; Humans; Intestinal Mucosa; Peptide YY; Quinolones; Rimonabant; Signal Transduction; Somatostatin; Stem Cells; Transcription Factors | 2022 |